Post-op PET CT & CT ‘moderately’ accurate in detecting recurrent pancreatic cancer
In a medical landscape where the prognosis of pancreatic ductal adenocarcinoma (PDAC) remains poor, postoperative CT and FDG PET-CT imaging could help detect disease recurrence, researchers reported in the European Journal of Radiology this summer. {read more here}
In metastatic breast cancer, prognosis and treatment is largely influenced by estrogen receptor (ER) expression of the metastases. However, little is known about ER expression across metastases throughout the body and surrounding normal tissue. Using a positron emission tomography (PET) tracer, researchers in the Netherlands have been able to identify differences in ER expression, which could help guide treatment for metastatic breast cancer patients. The study is featured in The Journal of Nuclear Medicine‘s August issue. {read more here}
Researchers have discovered a new nuclear medicine test that could improve care of patients with type 1 diabetes. The new positron emission tomography (PET) imaging method could measure beta-cell mass, which would greatly enhance the ability to monitor and guide diabetes therapies. This study is reported in the featured article of the month in The Journal of Nuclear Medicine‘s August issue. {read more here}
GE Healthcare and Lantheus have started a second Phase 3 clinical trial of flurpiridaz 18F, an investigational agent being evaluated for the detection of coronary artery disease. (read more here)